Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.
Ueda Oshima M, Storer BE, Qiu H, Chauncey T, Asch J, Boyer MW, Giaccone L, Flowers M, Mielcarek M, Storb R, Maloney DG, Sandmaier BM. Ueda Oshima M, et al. Transplant Cell Ther. 2021 Feb;27(2):163.e1-163.e7. doi: 10.1016/j.jtct.2020.10.016. Epub 2020 Dec 11. Transplant Cell Ther. 2021. PMID: 33830025 Free PMC article. Clinical Trial.
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.
Ueda Oshima M, Sandmaier BM, Petersdorf E, Flowers ME, Hill GR, Lee SJ, Appelbaum FR, Carpenter PA, Baker KS, Connelly-Smith L, McCool A, Elgar S, Pergam SA, Liu C, Stewart FM, Mielcarek M. Ueda Oshima M, et al. Bone Marrow Transplant. 2021 Feb;56(2):305-313. doi: 10.1038/s41409-020-01068-x. Epub 2020 Sep 26. Bone Marrow Transplant. 2021. PMID: 32980860 Free PMC article. Review.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: ueda oshima m. Blood. 2025 Jan 7:blood.2024025154. doi: 10.1182/blood.2024025154. Online ahead of print. Blood. 2025. PMID: 39775763
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.
Rosen EA, Krantz EM, McCulloch DJ, Wilson MH, Tverdek F, Kassamali Escobar Z, Drucker D, Sanchez E, Ueda Oshima M, Mielcarek M, Gauthier J, Pergam SA, Hill JA, Liu C. Rosen EA, et al. Among authors: ueda oshima m. Transplant Cell Ther. 2024 Nov;30(11):1108.e1-1108.e11. doi: 10.1016/j.jtct.2024.08.010. Epub 2024 Aug 22. Transplant Cell Ther. 2024. PMID: 39179107
Decreasing chronic graft-versus-host disease rates in all populations.
Carpenter PA, Gooley TA, Boiko J, Lee CJ, Burroughs LM, Mehta R, Salit RB, Bhatt NS, Krakow E, Dahlberg AE, Yeh AC, Summers CN, Ueda Oshima M, Petersdorf EW, Vo P, Connelly-Smith L, Lee SJ. Carpenter PA, et al. Among authors: ueda oshima m. Blood Adv. 2024 Nov 26;8(22):5829-5837. doi: 10.1182/bloodadvances.2024012722. Blood Adv. 2024. PMID: 39167805 Free PMC article.
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
Hamilton BK, Pandya BJ, Ivanescu C, Elsouda D, Hamadani M, Chen YB, Levis MJ, Ueda Oshima M, Litzow MR, Soiffer RJ, Ustun C, Perl AE, Singh AK, Geller N, Hasabou N, Rosales M, Cella D, Corredoira L, Pestana C, Horowitz MM, Logan B. Hamilton BK, et al. Among authors: ueda oshima m. Blood Adv. 2024 Oct 8;8(19):5091-5099. doi: 10.1182/bloodadvances.2024013746. Blood Adv. 2024. PMID: 39167766 Free PMC article. Clinical Trial.
17 results